MedPath

Cardiol Therapeutics' CardiolRx Shows Promise in Phase 2 Pericarditis Study

• Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pericarditis pain and inflammation over 26 weeks in a Phase 2 trial. • The MAvERIC-Pilot study results support the advancement of CardiolRx into late-stage clinical trials, including the pivotal Phase 3 MAVERIC-3 trial. • CardiolRx was shown to be safe and well-tolerated, strengthening the case for its continued development as a treatment for recurrent pericarditis and acute myocarditis.

Cardiol Therapeutics has received a Buy rating from H.C. Wainwright analyst Vernon Bernardino following positive Phase 2 results for CardiolRx in the MAvERIC-Pilot study. The data indicated significant and sustained improvements in pericarditis pain and inflammation, maintained over a 26-week period. These findings support the advancement of CardiolRx into late-stage clinical trials, including the pivotal Phase 3 trial, MAVERIC-3.

Phase 2 Trial Results

The MAvERIC-Pilot study demonstrated that CardiolRx was safe and well-tolerated. The successful results suggest a promising future for CardiolRx as a potential treatment for recurrent pericarditis and acute myocarditis. The company's financial position, bolstered by a recent public offering, provides a stable foundation for its upcoming trials.

Analyst's Perspective

Bernardino's Buy rating is based on the positive clinical results of Cardiol Therapeutics’ CardiolRx in the MAvERIC-Pilot study. The data from this Phase 2 study demonstrated significant and sustained improvements in pericarditis pain and inflammation, which were maintained over a 26-week period. These findings are crucial as they support the advancement of CardiolRx into late-stage clinical trials, including the pivotal Phase 3 trial, MAVERIC-3.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cardiol Therapeutics Leadership Invests Following Positive Phase II Pericarditis Trial Data

Cardiol Therapeutics executives and board members increased their holdings after promising Phase II trial results for CardiolRx™ in recurrent pericarditis.
The MAvERIC-Pilot trial demonstrated significant reductions in pericarditis pain and C-reactive protein levels, with a favorable safety profile.

Assertio Therapeutics Receives Buy Rating Following Positive Clinical Trial Results

H.C. Wainwright reaffirms a Buy rating for Assertio Therapeutics, citing promising clinical trial outcomes for ROLVEDON in early-stage breast cancer treatment, with a price target of $4.00.

CardiolRx Shows Promise in Recurrent Pericarditis: Phase II MAvERIC-Pilot Study Results

Cardiol Therapeutics' CardiolRx demonstrated lasting improvements in pericarditis symptoms over a 26-week extension in the Phase II MAvERIC-Pilot study.
The study reported that 71% of patients remained recurrence-free when transitioned to CardiolRx monotherapy, highlighting the drug's potential effectiveness.

Cardiol Therapeutics' CardiolRx Shows Sustained Efficacy in Recurrent Pericarditis, Poised for Phase III Trials

Cardiol Therapeutics' CardiolRx demonstrated sustained pain relief in recurrent pericarditis patients over six months, with average pain scores decreasing from 5.8 to 1.5.
The MAvERIC trial data suggests CardiolRx performs favorably compared to rilonacept in pain reduction and CRP level normalization.

Cardiol Therapeutics' CardiolRx Shows Promise in Phase II Trial for Recurrent Pericarditis

Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pain and inflammation in patients with recurrent pericarditis during a Phase II open-label study.
The trial showed a substantial reduction in pericarditis episodes per year, from 5.8 to 0.9, with 71% of participants maintaining freedom from recurrence during the extension period.

Cardiol Therapeutics' CardiolRx Shows Promise in Phase II Recurrent Pericarditis Trial

Cardiol Therapeutics announced positive Phase II MAvERIC-Pilot study results, demonstrating CardiolRx's sustained efficacy in treating symptomatic recurrent pericarditis.
The study showed marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial period.

CardiolRx Shows Promise in Recurrent Pericarditis: Phase II MAvERIC-Pilot Study Results

Cardiol Therapeutics' CardiolRx demonstrated sustained improvements in pericarditis pain and inflammation over 26 weeks in a Phase II trial.
The MAvERIC-Pilot study showed a significant reduction in pericarditis episodes per year compared to pre-trial rates.

Cardiol Therapeutics' CardiolRx Shows Promise in Recurrent Pericarditis

Phase II MAvERIC-Pilot study demonstrates sustained improvements in pericarditis pain and inflammation with CardiolRx™ over 26 weeks.
Patients experienced clinically relevant and rapid reductions in pericarditis pain and C-reactive protein (CRP) levels, maintained throughout the study.

CardiolRx Shows Promise in Recurrent Pericarditis: Phase II Trial Results

Cardiol Therapeutics' CardiolRx demonstrated significant pain reduction in recurrent pericarditis patients, decreasing pain scores from 5.8 to 1.5 by week 26.
The Phase II MAvERIC-Pilot study showed CRP normalization in 80% of patients by week 8, indicating a reduction in inflammation.

Cardiol Therapeutics Launches Phase II/III Trial for Recurrent Pericarditis

Cardiol Therapeutics has initiated the MAVERIC-2, a pivotal phase II/III clinical trial, targeting patients with recurrent pericarditis who have discontinued interleukin-1 blocker therapies.
The MAVERIC-2 trial aims to evaluate CardiolRx as a potentially more effective and cost-efficient treatment alternative for recurrent pericarditis, addressing a high recurrence rate.

Reference News

[1]
Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong ...
markets.businessinsider.com · Nov 20, 2024

Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics (CRDL) with a $9.00 price target,...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy